Published in Cancer Res on September 01, 2008
Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 8.55
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene (2010) 2.11
Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol (2009) 1.91
Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol (2013) 1.59
Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res (2012) 1.58
Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene (2009) 1.51
ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med (2011) 1.47
Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res (2010) 1.23
Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers. PLoS One (2012) 1.10
Functional characterization of the 19q12 amplicon in grade III breast cancers. Breast Cancer Res (2012) 1.06
bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database (Oxford) (2013) 1.05
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biol (2015) 0.97
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat (2015) 0.93
Genomic organization and evolution of double minutes/homogeneously staining regions with MYC amplification in human cancer. Nucleic Acids Res (2014) 0.91
Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. Breast Cancer Res (2012) 0.90
POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature. Leukemia (2010) 0.90
Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis (2013) 0.89
Frequent MYC coamplification and DNA hypomethylation of multiple genes on 8q in 8p11-p12-amplified breast carcinomas. Oncogenesis (2014) 0.89
Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. PLoS One (2014) 0.87
Targeting RTK Signaling Pathways in Cancer. Cancers (Basel) (2015) 0.85
Evidence for the importance of personalized molecular profiling in pancreatic cancer. Pancreas (2014) 0.83
Genetic characterization of breast cancer and implications for clinical management. J Cell Mol Med (2009) 0.81
Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. PLoS One (2012) 0.81
Polarity gene alterations in pure invasive micropapillary carcinomas of the breast. Breast Cancer Res (2014) 0.80
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer. Breast Cancer Res (2014) 0.80
Enumerating the gene sets in breast cancer, a "direct" alternative to hierarchical clustering. BMC Genomics (2010) 0.77
Genome-wide DNA methylation profiles according to Chlamydophila psittaci infection and the response to doxycycline treatment in ocular adnexal lymphoma. Mol Vis (2014) 0.77
Integrated genomic analysis of breast cancers. Balkan J Med Genet (2012) 0.75
Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer. Mol Oncol (2016) 0.75
Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer. Oncogene (2016) 0.75
The PWWP domain of the human oncogene WHSC1L1/NSD3 induces a metabolic shift toward fermentation. Oncotarget (2016) 0.75
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics (2004) 8.29
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol (2010) 4.93
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Protein interaction mapping: a Drosophila case study. Genome Res (2005) 4.15
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol (2004) 3.33
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol (2009) 3.07
Mesenchymal stem cell features of Ewing tumors. Cancer Cell (2007) 3.04
MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res (2011) 3.02
A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res (2007) 2.88
Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics (2011) 2.86
Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization. Bioinformatics (2010) 2.79
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data. Bioinformatics (2010) 2.63
Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res (2012) 2.55
A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet (2012) 2.45
Regional copy number-independent deregulation of transcription in cancer. Nat Genet (2006) 2.33
An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell (2013) 2.30
Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev (2011) 2.29
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol (2012) 2.29
Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol (2009) 2.21
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res (2008) 2.16
Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol (2009) 2.15
Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A (2012) 2.13
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 2.12
Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro Oncol (2009) 2.04
Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet (2004) 1.98
Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol (2007) 1.97
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res (2008) 1.94
Columnar cell lesions of the breast. Adv Anat Pathol (2003) 1.92
A "class action" against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev (2008) 1.91
VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics (2006) 1.87
ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res (2012) 1.86
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol (2013) 1.83
Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol (2002) 1.82
Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med (2010) 1.81
Spatial normalization of array-CGH data. BMC Bioinformatics (2006) 1.79
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res (2010) 1.79
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res (2012) 1.78
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet (2005) 1.74
MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One (2009) 1.73
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer (2008) 1.72
High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. J Clin Oncol (2012) 1.71
Bayesian hierarchical model for identifying changes in gene expression from microarray experiments. J Comput Biol (2002) 1.70
Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet (2013) 1.69
Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res (2004) 1.68
Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res (2007) 1.68
BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer (2008) 1.66
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol (2010) 1.65
FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res (2003) 1.64
The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS One (2009) 1.63
A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol Syst Biol (2008) 1.61
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res (2009) 1.61
Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res (2012) 1.58
Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res (2007) 1.58
Management of phyllodes breast tumors. Breast J (2011) 1.58
Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol (2003) 1.58